Davis Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Davis Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$108	Buy	+6	New	+$113	﹤0.01%	1045

Other funds holding SRPT

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Davis Capital Management's SRPT Position: Q2 2026 in Review

Davis Capital Management opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 6 shares worth $108. The stake represents ﹤0.01% of the portfolio and ranks #1045 among its holdings.

49 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Davis Capital Management held 6 shares of Sarepta Therapeutics worth $108 as of Q2 2026.
Sarepta Therapeutics was a new Davis Capital Management position in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #1045 holding.
49 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.